Financial Data and Key Metrics Changes - The company reported worldwide revenue of $1,036 million for Q1 2025, a 12% increase compared to $921 million in Q1 2024, with organic revenue growth of 14% [18] - U.S. revenue totaled $751 million, up 15% from $653 million in Q1 2024, driven by strong new customer demand [19] - International revenue grew 7% to $286 million, with organic growth of 12% [21] - Gross profit was $596.2 million, representing 57.5% of revenue, down from 61.8% in Q1 2024 [23] - Operating income was $143.1 million, or 13.8% of revenue, compared to $140.2 million in the same quarter of 2024 [24] - Adjusted EBITDA was $230.4 million, or 22.2% of revenue, compared to $220.9 million, or 24% of revenue in Q1 2024 [25] - Net income for Q1 was $127.7 million, or $0.32 per share [26] Business Line Data and Key Metrics Changes - The company experienced record levels of new customer demand, particularly from the Type 2 non-insulin using population [9][10] - The introduction of Stello, the first over-the-counter CGM, and broader access in the Type 2 market contributed to increased customer starts [10][12] - The company launched a 180-day data look-back feature for the Stello app, enhancing customer experience [13] Market Data and Key Metrics Changes - The company secured access at two of the three largest PBMs for diabetes patients, which is expected to cover nearly six million people with Type 2 diabetes by the end of the year [10][11] - International business showed strength in Japan and France, with continued growth in the Type 2 landscape [22] Company Strategy and Development Direction - The company is focused on expanding coverage for Type 2 diabetes patients and enhancing customer experience through technology and software updates [10][12] - The introduction of the 15-day G7 system is expected to set a new industry standard for sensor accuracy and wear time [16] - The company is committed to addressing FDA concerns following a warning letter and is working on corrective actions [15][102] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply dynamics and maintaining customer care during the transition period [6][19] - The company reaffirmed its revenue guidance of $4.6 billion for the year, representing 14% growth, while adjusting gross margin guidance to approximately 62% [27][29] - Management is optimistic about the potential for broader Type 2 coverage and the positive reception of CGM technology in the healthcare landscape [10][110] Other Important Information - The company announced a $750 million share repurchase program, reflecting strong cash flow and financial position [26] - Management highlighted the importance of evidence-based data in driving changes to standards of care and expanding access globally [11] Q&A Session Summary Question: Did supply have any impact on the revenue growth? - Management indicated that supply dynamics were normalized by the end of the quarter, and strong new patient performance was observed despite previous challenges [35] Question: Why is full-year guidance unchanged despite strong Q1 growth? - Management stated that it is prudent to wait and see how the year unfolds before adjusting guidance, emphasizing the importance of a full-year perspective [42] Question: What are the trends in Type 2 patient utilization and reorder rates? - Management reported good retention and utilization rates among Type 2 patients, particularly those with reimbursement coverage [50] Question: How exposed is the company to a potential recession? - Management believes the company is well-positioned to weather economic downturns due to the cost-saving benefits of its products [58][60] Question: What is the status of the FDA warning letter? - Management confirmed that the warning letter does not restrict new submissions or approvals and that they are making progress in addressing FDA concerns [102] Question: What is the timeline for the RCT data readout for Type 2 non-insulin users? - Management anticipates finishing enrollment in the first half of the year, with initial data readout expected late this year or early next year [112]

Hologic (HOLX) Q2 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Hologic's Second Quarter Fiscal twenty twenty five Earnings Conference Call. My name is Rachel, and I'm your operator for today's call. Today's conference is being recorded. All lines have been placed on mute. I would now like to introduce Mike Watts to begin the call. Speaker1 Thank you, Rachel. Good afternoon and thank you for joining Hologic's second quarter fiscal twenty twenty five earnings call. With ...

Ascendis Pharma (ASND) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Ladies and gentlemen, thank you for standing by, and welcome to Ascendis Pharma First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To w ...

Alphatec (ATEC) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, everyone, and welcome to the webcast of ATEC's First Quarter Financial Results. We would like to remind everyone that participants on the call will make forward looking statements. These statements are based on current expectations and are subject to uncertainties that could cause actual results to differ materially. These uncertainties are detailed in documents filed regularly with the SEC. During this call, you may hea ...

Riot Platforms (RIOT) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good day and thank you for standing by. Welcome to the Riot Platform's First Quarter twenty twenty five Earnings Conference Call. Please note that all participants have been placed in listen only mode until the question and answer session begins following the company's presentation of its prepared remarks. Please also be advised that today's call is being recorded. I would now like to hand the conference over to Phil McPherson, Vi ...

Five9 (FIVN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Thank you for joining us today. Certain statements made during the course of this conference call that are not historical facts, including those regarding the future financial performance and cash position of the company, expected improvements in financial and related metrics, expected ARR from certain customers, certain expected revenue mix shifts, customer growth, anticipated customer benefits from our solution, including from AI, the ex ...

Grid Dynamics (GDYN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, everyone. Welcome to Grid Dynamics First Quarter twenty twenty five Earnings Conference Call. I'm Cary Savas, Director of Branding and Communications. Joining us on the call today are CEO, Leonard Lifshitz CFO, Anil Dorado CTO, Eugene Steinberg and SVP, Americas, Vasily Sizov. Following the prepared remarks, we will open the call to your questions. Please note that today's conference call is being recorded. Statemen ...

Amgen (AMGN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 My name is Julianne, and I will be your conference facilitator today for the Amgen Q1 FY twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. There will be a question and answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question durin ...

Asure Software (ASUR) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to Asure's First Quarter twenty twenty five Earnings Conference Call. Joining us for today's call are Chairman and CEO, Pat Gopel Chief Financial Officer, John Pence and Vice President of Investor Relations, Patrick McKillop. Following their prepared remarks, there will be a question and answer session for the analysts and investors. I would now like to turn the call over to Patrick McKillop for introdu ...

El Pollo Loco (LOCO) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good day ladies and gentlemen and thank you for standing by. Welcome to the El Polo Loco First Quarter twenty twenty five Earnings Conference Call. At this time, all participants have been placed in a listen only mode and the lines will be open for your questions following the presentation. Please note that this conference is being recorded today, 05/01/2025. And now I would like to turn the conference over to Ira Phills, the compa ...